Search

Your search keyword '"Costagliola D"' showing total 1,303 results

Search Constraints

Start Over You searched for: Author "Costagliola D" Remove constraint Author: "Costagliola D"
1,303 results on '"Costagliola D"'

Search Results

1. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

4. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

5. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

6. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.

7. EE485 Cost-Effectiveness of a 4 Days-a-Week Triple Therapy in Persons Living with HIV: An Ancillary Study of the Anrs 170 Quatuor Noninferiority Trial

8. High Prevalence of Anal Human Papillomavirus–Associated Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-Infected Women

9. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

10. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries.

11. Blunted response to combination antiretroviral therapy in HIV elite controllers: An international HIV controller collaboration

13. Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort

14. Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia

19. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

21. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

22. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

23. SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine-based PrEP in 2020 - a sub-study of PREVENIR-ANRS and SAPRIS-Sero

24. Perception of PrEP‐related stigma in PrEP users: Results from the ANRS‐PREVENIR cohort.

26. Comparison of HIV-Infected and Noninfected Patients Undergoing Bariatric Surgery: The ObeVIH Study

27. Key findings on bipolar disorders from the longitudinal FondaMental Advanced Center of Expertise-Bipolar Disorder (FACE-BD) cohort

28. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

29. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial)

30. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

31. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

32. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

33. Association between Vitamin D Receptor Gene Polymorphisms and Periodontal Bacteria: A Clinical Pilot Study

34. Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression

35. Higher rates of triple‐class virological failure in perinatally HIV‐infected teenagers compared with heterosexually infected young adults in Europe

36. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

38. Single-Nucleotide Polymorphism-Defined Class I and Class III Major Histocompatibility Complex Genetic Subregions Contribute to Natural Long-term Nonprogression in HIV Infection

40. Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study

41. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

43. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

44. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

45. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

46. CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies

49. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

50. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

Catalog

Books, media, physical & digital resources